Latest "Pharmaceutical Executive Conferences website" News Stories - Page: 5

02:35 EDT 16th September 2019 | BioPortfolio

Here are the most relevant search results for "Pharmaceutical Executive Conferences website" found in our extensive news archives from over 250 global news sources.

More Information about Pharmaceutical Executive Conferences website on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Pharmaceutical Executive Conferences website for you to read. Along with our medical data and news we also list Pharmaceutical Executive Conferences website Clinical Trials, which are updated daily. BioPortfolio also has a large database of Pharmaceutical Executive Conferences website Companies for you to search.

Showing "Pharmaceutical Executive Conferences website" News Articles 101–125 of 16,000+

Thursday 12th September 2019

Company Profile for Le Herbe

Le Herbe is the world's most trusted expert on water soluble cannabinoids. Company:   Le Herbe       Headquarters Address:   8429 Lorraine Rd. #10

SCORR Marketing and the Conference Forum to Collaborate on CRAACO Conference

A Shared Mission of Unifying Clinical Research and Clinical Care SCORR Marketing, the leading full-service marketing and communications firm in the health science industry, and the Conference Forum, the leading

Medidata and Mapi Research Trust (MRT) Announce Strategic Collaboration to Standardize eCOA Global Library of Questionnaires

Faster, Simpler, Better: Dramatically Reduce Timelines, Simplify Study Start up, and Increase Quality in Hundreds of Clinical Trials Each Year New Medidata and MRT collaboration will seek to solve eCOA implementation challenges and cut timelines by 50-60% with pre-approved and pre-translated instruments MRT library of patient-centered questionnaires to be standardized in Medidata Rave eCOA ...

X4 Pharmaceuticals to Present Phase 2a Data for Mavorixafor in Combination with Axitinib at European Society for Medical Oncology (ESMO) 2019 Congress

Management to host investor conference call and webcast on Monday, September 30 at 8:00 AM EDT / 2:00 PM CEST X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical stage biotechnology company focused on the development of novel therapeutics for the treatment of rare diseases, today announced it will present clinical data on its lead product candidate, mavorixafor (X4P-001), in combination with In...

Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals

Acquisition Gives Aytu Timely Entry into Growing Consumer Healthcare Market with a Portfolio of Over 30 Products that Generated $24M of Revenue During Past Four Quarters Combination Will Create Specialty Rx and Consumer Pharma Company with Revenue of $31M New Products, Robust Cross-Selling, and Operational Efficiencies Designed to Accelerate Time to Profitability Aytu BioScience, Inc. (NASD...

WellStar Health System Expands Use of Glytec’s eGlycemic Management System®

Georgia’s largest health system is heightening the safety and efficacy of insulin therapy across its network of hospitals. Known nationally for innovative care models, WellStar Health System, in partnership with

Meitheal Pharmaceuticals Announces Launch of Heparin Sodium Injection, USP in the United States

Meitheal Pharmaceuticals (“Meitheal”), a fully integrated generic injectables company today announced the launch of the Company’s eight presentations of heparin sodium injection, USP in the United States (US). “We are pleased to be able to provide a vital anticoagulant for patients across the country,” said Tom Shea, founding Chief Executive Officer of Meitheal

Certara Launches Version 8.2 of Its Industry-Leading Phoenix PK/PD Modeling and Simulation Software for Drug Development

Aligned with newly issued FDA Draft Guidance, Phoenix supports electronic data, methods and results audit, traceability and communication requirements Certara®, the global model-informed drug development and decision support leader, today announced the launch of Phoenix® 8.2, the industry gold standard in pharmacokinetic/pharmacodynamic (

Navitor’s Three Phase 1 Studies for NV-5138 Show Antidepressant Effects and Biomarker Impact, Supporting Further Development of Direct Activator of mTORC1 in Depression

- Single Dose NV-5138 Shows Rapid and Sustained Improvement on Core Symptoms of Depression with Favorable Safety and Tolerability in Patients with Treatment-Resistant Depression (TRD) - Single Dose NV-5138 Shows Rapid and Sustained Target Engagement on Key Biomarkers and Impact on Quantitative Electroencephalogram Activity in Healthy Normal Volunteers Navitor Pharmaceuticals, Inc., the leader ...

AstraZeneca, Learning Undefeated and Discovery Education Launch New Generation Health Program to Encourage Healthy Living Through Science-Based Learning

SOURCE: Discovery Education DESCRIPTION:Silver Spring, Md., Thursday, September 12, 2019 /3BL Media/– AstraZeneca, Learning Undefeated and Discovery Education, the leading provider of standards-aligned digital curriculum resources, engaging content and professional learning for K-12 classrooms, today launched Generation Health: How Science Powers Us, a dynamic program designed to make the connec...

Global CDMO Outsourcing Market 2019-2023 | 8% CAGR Projection Over the Next Five Years | Technavio

The global contract development and manufacturing organization (CDMO) outsourcing market is poised to reach USD 36.51 billion by 2023, according to a new report by Technavio, progressing at a CAGR of close to 8% during the forecast period. This press release features multimedia. View the full release he

FDA grants Orphan Drug Designation to sotatercept

Orphan Drug Designation has been given to sotatercept for the treatment of patients with pulmonary arterial hypertension. The post FDA grants Orphan D

Walgreens to Offer 3 Percent Daily Cash on Apple Card with Apple Pay Purchases

Starting on Friday, September 13, Walgreens customers will receive 3 percent Daily Cash when they use Apple Card with Apple Pay on eligible purchases, including prescriptions, made in Walgreens and Duane Reade stores, and for purchases made on the Walgreens app and on Walgreens is the only retail pharmacy to offer 3 percent Daily Cash on Apple Card with Apple Pay purchases. Apple...

Aruna Bio to Present at Exosome Based Therapeutic Development Summit

Presentation will highlight the potential utilization of exosomes as a therapeutic and delivery vehicle for treating neurodegenerative diseases Aruna Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, today announced that Dr. Steven Stice, Co-Founder and Chief Scientific Officer, will be giving a presentation at the Exosome Based Therapeuti...

Newron Reports Half-Year 2019 Results

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its results for the half year ended June 30, 2019. Half Year 2019 Highlights Sarizotan (Rett Syndrome) Successfully completed enrollment of 129 patients in the STARS (Sari...

Bristol-Myers Squibb to Announce Results for Third Quarter 2019 on October 31, 2019

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2019 on Thursday, October 31, 2019. During a conference call at 8:30 a.m. ET on October 31, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast of the call at

Vertex cystic fibrosis drugs become available in Scotland after NHS rejection

Two potentially life-changing cystic fibrosis drugs are to become available for a potential pool of 400 patients in Scotland just a month after they were rejected by the NHS. Boston-based pharmaceutical company Vertex has announced it has signed a five-year deal with the Scottish Government for Orkambi and Symkevi (lumacaftor/ivacaftor) – drugs which help improve lung health, but were to cost ab...

VBI Vaccines announces phase 2a trial of VBI-1901 plus AS01B adjuvant system in recurrent glioblastoma

As part of the collaboration, VBI plans to add an additional study arm to Part B of the company’s ongoing, multi-center, open-label Phase 1/2a clinical study targeting recurrent The post VBI Vaccines announces phase 2a trial of VBI-1901 plus AS01B adjuvant system in recurrent glioblastoma appeared first on Pharmaceutical Business review.

Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)

mRNA-1944 successfully encoded for functional antibody (CHKV-24) in humans at all dose levels tested (0.1, 0.3 and 0.6 mg/kg) Antibody level predicted to protect against chikungunya infection achieved within hours; projected to be maintained for at least 16 weeks at the middle and high doses No significant adverse events were observed at the low and middle doses; infusion-related adverse eve...

Innovative Industrial Properties Acquires California Property Portfolio and Enters into Long-Term Leases with Vertical

Acquisition Expands Footprint to 2.2 Million Square Feet in Twelve States Innovative Industrial Properties, Inc. (IIP), the first and only real estate company on the New York Stock Exchange (NYSE: IIPR) focused on the regulated U.S. cannabis industry, announced today that it closed on the final parcel of a four-property portfolio in southern California, which comprises approximately 79,000 squar...

Transcat, Inc. to Present at Sidoti & Company Fall 2019 Conference

Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professional grade handheld test, measurement and control instrumentation, announced that Lee D. Rudow, President and Chief Executive Officer, and Michael J. Tschiderer, Chief Financial Officer, will...

Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials

Vaccination immunized seronegative participants to levels consistent with or above seropositive titers and boosted baseline titers in seropositive participants Vaccine was generally well-tolerated Phase 2 study to confirm dose to be initiated in near term, with planned interim analysis through 3 months; Phase 3 study planning is underway CMV is the most common infectious cause of birth defe...

Hansoh Pharma, Atomwise launch AI drug discovery collaboration for multiple therapeutic areas

Scientific teams from Atomwise and Hansoh Pharma will work closely together on the programs. The combination of complementary expertise and technologies has the potential to dramatically increase success The post Hansoh Pharma, Atomwise launch AI drug discovery collaboration for multiple therapeutic areas appeared first on Pharmaceutical Business review.

UK Government confirms disruption to medicines in event of no-deal Brexit

A document published by the UK Government laying out the worst case scenario if the UK leaves the European Union...Read More... The post UK Government confirms disruption to medicines in event of no-deal Brexit appeared first on Pharmaceutical Technology.

NHS agrees to fund drug for children with incurable Batten disease

The NHS in the UK has agreed to fund a drug for children with a rare degenerative disease, which leads...Read More... The post NHS agrees to fund drug for children with incurable Batten disease appeared first on Pharmaceutical Technology.

Quick Search

News Quicklinks